ReviewJournal of clinical medicine2022
Pharmacological Treatment in Presbyopia.
Review in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 35 citations in OpenAlex.
- Enhancing presbyopia treatment: A comparative study of 1% Pilocarpine monotherapy versus combination with 0.09% Bromfenac.Indian journal of ophthalmology · 2026Trial
- Trial
- Extract fromNutrients · 2024Trial
- Combination Low-Dose Pilocarpine/Diclofenac Sodium and Pilocarpine Alone for Presbyopia: Results of a Randomized Phase 2b Clinical Trial.Clinical ophthalmology (Auckland, N.Z.) · 2024Trial
- Comments on "Enhancing presbyopia treatment: A comparative study of 1% Pilocarpine monotherapy versus combination with 0.09% bromfenac".Indian journal of ophthalmology · 2026Article
- Current Trends in Presbyopia Correction-A Comprehensive Review.Journal of clinical medicine · 2025Review
- Sirius Cutting Mode enhances vision and reduces myopia severity through personalized treatment.American journal of translational research · 2025Article
- Female predominance and socio-demographic inequalities in global near vision loss burden: projected trends and disparities from 1990 to 2035.Frontiers in public health · 2025Article
- Pilocarpine 1% for Improved Near Vision in Pseudophakic Patients.Journal of ophthalmic & vision research · 2025Article
- Interventions to prevent visual fatigue during robotic surgery.Journal of robotic surgery · 2024Review
- Understanding Perspectives on Presbyopia and Use of Pilocarpine HCl 1.25% Twice Daily from Participants of the Phase 3 VIRGO Study.Ophthalmology and therapy · 2024Article
- Psychometric evaluation of the near activity visual questionnaire presbyopia (NAVQ-P) and additional patient-reported outcome items.Journal of patient-reported outcomes · 2024Article
- Adrenoceptors in the Eye - Physiological and Pathophysiological Relevance.Handbook of experimental pharmacology · 2024Review
- Visual satisfaction with progressive addition lenses prescribed with novel foveal fixation axis measurements.Scientific reports · 2023Article
- Non-Miotic Improvement in Binocular Near Vision with a Topical Compound Formula for Presbyopia Correction.Ophthalmology and therapy · 2023Article
- Presbyopia: What We Do Know and What We Do Not Know in 2022.Journal of clinical medicine · 2023Article
- Google Search Trends to assess public interest in and concern about Vuity for treating presbyopia.PloS one · 2023Article
- Article
- Correction of presbyopia.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2022Article
- An updated systematic review of pharmacological treatments for presbyopia.Advances in ophthalmology practice and researchReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pharmacological treatment of presbyopia may be an alternative for those who want a spectacle-free scenario and an easy-to-use method with lower risk of irreversible ocular adverse events. There are two main agents, miotics and lens softeners, investigated as agents for the pharmacological treatment. Miotic agents treat presbyopia by creating a pinhole effect which may increase the depth of focus at all working distances. The miotic agents have been studied for application to only one eye for monovision or both eyes. Their effect is temporary with common adverse events, such as headache and dim vision at nighttime, with no known long-term safety and efficacy. There have been studies on the miotic agents in combination with other agents for additive treatment effects or lessening adverse events, however, these combination effects are not clear. Lens softeners increase the elasticity of the lens, which is targeted at one of the etiologic mechanisms of presbyopia. There is only one lens softener being investigated in only a few trials. The results were inconclusive. The recent approval of 1.25% pilocarpine for treatment of presbyopia by the US FDA may be an important milestone for investigation of real-world data of pharmacological treatment of presbyopia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.